Crizotinib
- Generic Name
- Crizotinib
- Brand Names
- Xalkori
- Drug Type
- Small Molecule
- Chemical Formula
- C21H22Cl2FN5O
- CAS Number
- 877399-52-5
- Unique Ingredient Identifier
- 53AH36668S
- Background
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusio...
- Indication
Crizotinib is a kinase inhibitor indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. Crizotinib is also indicated for the treatment of relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK...
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer, Refractory Anaplastic Large Cell Lymphoma, Recurrent Inflammatory Myofibroblastic Tumors, Refractory Inflammatory Myofibroblastic Tumors, Relapsed Anaplastic Large Cell Lymphoma, Unresectable Inflammatory Myofibroblastic Tumors
- Associated Therapies
- -
Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer
- First Posted Date
- 2018-08-24
- Last Posted Date
- 2023-12-27
- Lead Sponsor
- Hunan Province Tumor Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT03646994
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
Phase II Umbrella Study Directed by Next Generation Sequencing
- First Posted Date
- 2018-07-02
- Last Posted Date
- 2022-12-06
- Lead Sponsor
- Guangdong Association of Clinical Trials
- Target Recruit Count
- 400
- Registration Number
- NCT03574402
- Locations
- 🇨🇳
Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, Guangdong, China
Safety and Efficacy of Xalkori ROS1
- First Posted Date
- 2017-12-18
- Last Posted Date
- 2024-08-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT03375242
- Locations
- 🇯🇵
Pfizer local country office, Tokyo, Japan
Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
- Conditions
- Interventions
- First Posted Date
- 2017-09-29
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 720
- Registration Number
- NCT03297606
- Locations
- 🇨🇦
Verspeeten Family Cancer Centre, London, Ontario, Canada
🇨🇦Cross Cancer Institute, Edmonton, Alberta, Canada
🇨🇦BCCA - Kelowna, Kelowna, British Columbia, Canada
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
- First Posted Date
- 2017-06-21
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 200
- Registration Number
- NCT03194893
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center; UC Irvine Medical Center, Orange, California, United States
🇺🇸Miami Cancer Institute of Baptist Health, Inc., Miami, Florida, United States
🇨🇳Guangdong General Hospital, Guangzhou, China
A Study to Evaluate the Effects of Food and Esomeprazole on the Pharmacokinetics of Crizotinib in a Coated Microsphere Formulation.
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT03137134
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer
- First Posted Date
- 2017-03-23
- Last Posted Date
- 2022-02-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 3
- Registration Number
- NCT03088930
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
Treatment With Crizotinib Single Patient Expanded Access IND 134375
- Conditions
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2017-08-29
- Lead Sponsor
- Jean M. Tersak, M.D.
- Registration Number
- NCT03085186
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
- Conditions
- Interventions
- First Posted Date
- 2017-02-14
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 296
- Registration Number
- NCT03052608
- Locations
- 🇺🇸
The William P. Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, United States
🇺🇸Ophthalmic Consultants of Boston Inc, Boston, Massachusetts, United States
🇺🇸University of Washington Medical Center, Seattle, Washington, United States
The Drug Rediscovery Protocol (DRUP Trial)
- Conditions
- Interventions
- Drug: PanitumumabDrug: OlaparibDrug: CrizotinibDrug: ErlotinibDrug: AlectinibDrug: Ipilimumab and nivolumabDrug: SunitinibDrug: Trastuzumab and Pertuzumab (combination treatment)Drug: Vemurafenib and Cobimetinib (combination treatment)Drug: NivolumabDrug: Dabrafenib and trametinibDrug: SelpercatinibDrug: TepotinibDrug: AbemaciclibDrug: ErdafitinibDrug: Atezolizumab and BevacizumabDrug: DacomitinibDrug: DabrafenibDrug: NilotinibDrug: TrametinibDrug: VismodegibDrug: RegorafenibDrug: AfatinibDrug: RibociclibDrug: LenvatinibDrug: PembrolizumabDrug: DurvalumabDrug: RucaparibDrug: AxitinibDrug: PalbociclibDrug: CabozantinibDrug: EntrectinibDrug: TalazoparibDrug: LorlatinibDrug: AlpelisibDrug: NiraparibDrug: Pemigatinib
- First Posted Date
- 2016-10-05
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 1550
- Registration Number
- NCT02925234
- Locations
- 🇳🇱
Meander medisch centrum, Amersfoort, Netherlands
🇳🇱Netherlands Cancer Institute, Amsterdam, Netherlands
🇳🇱Amsterdam UMC, locatie AMC, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.